Operator
Thanks for standing by. That is the convention operator. Welcome to Zymeworks convention name and webcast to debate the acquisition of Theravance Biopharma. [Operator Instructions] The convention is being recorded. I’d now like to show the convention over to Shrinal Inamdar, Vice President of Investor Relations. Shrinal, please go forward.
Shrinal Inamdar
VP of Investor Relations
Thanks, operator. Good afternoon, everybody, and thanks for becoming a member of. Throughout as we speak’s name, Ken Galbraith, our Chair and CEO, will present an summary of the strategic rationale for the proposed acquisition of Theravance Biopharma by Zymeworks as introduced by press launch this morning.
Scott Platshon, our Chief Enterprise Officer, will then present a deeper understanding of Theravance’s enterprise and the worth of its underlying belongings and money flows. Lastly, Kristin Stafford, our Chief Monetary Officer, will present an summary of the important thing phrases of the non-recourse financing with OMERS Life Sciences, after which we’ll open up the ground for Q&A on the finish.
As traditional, I might prefer to remind you that this name will comprise forward-looking statements, together with, with out limitation, these forward-looking statements recognized in our slides and the accompanying oral commentary. Ahead-looking statements are based mostly on our present expectations and varied
